To date, the COG has only investigated a MEK inhibitor for acute leukemia through one of its registered studies, which is an ongoing Phase II trial of trametinib in r/r juvenile myelomonocytic leukemia (JMML). Here, MAP2K7 is linked to juvenile myelomonocytic leukemia.